GENOME MACRORESTRICTION ANALYSIS OF DIVERSITY AND VARIABILITY OF PSEUDOMONAS-AERUGINOSA STRAINS INFECTING CYSTIC-FIBROSIS PATIENTS

被引:110
作者
STRUELENS, MJ [1 ]
SCHWAM, V [1 ]
DEPLANO, A [1 ]
BARAN, D [1 ]
机构
[1] HOP ERASME,SERV PNEUMOL,UNITE MUCOVISCIDOSE,B-1070 BRUSSELS,BELGIUM
关键词
D O I
10.1128/JCM.31.9.2320-2326.1993
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Genome macrorestriction fingerprinting with XbaI and DraI was used to analyze the relatedness of 166 Pseudomonas aeruginosa isolates collected from 31 cystic fibrosis patients over a 1- to 20-month period and to correlate their genotype with patterns of resistance to 14 antimicrobial agents. Quantitative comparison of intra- and interpatient similarities of P. aeruginosa macrorestriction patterns disclosed two discrete ranges that clearly discriminated subclonal variation (>80% relatedness) and clonal diversity (10 to 70% relatedness). Cloning-derived mutants exhibited up to 20% divergence of genomic macrorestriction patterns during the course of chronic colonization of individual patients. Change of susceptibility to multiple antimicrobial agents developed in 50% of sequential pairs of isolates from individual patients. Only 19% of these susceptibility changes were attributable to strain substitution, while the majority (56%) of resistance changes were associated with minor genomic variations of a persistent strain. Sixty-six percent of patients harbored one strain, and 33% carried two strains. Three common strains colonized 5 (28%) of 18 patients attending a cystic fibrosis clinic, and another two strains colonized two patient pairs (31%) of 13 patients staying at a rehabilitation center, suggesting potential cross-infection in these settings. By indexing regional polymorphisms throughout the chromosome structure, macrorestriction analysis can monitor subclonal evolution of P. aeruginosa and identify isogenic resistance mutants. Quantitative macrorestriction fingerprinting enables discrimination between clonal variants and clones of distinct origins and should therefore provide a reliable tool for investigating the mode of acquisition of P. aeruginosa in cystic fibrosis patients.
引用
收藏
页码:2320 / 2326
页数:7
相关论文
共 21 条
[1]   2 FORMS OF ANTIMICROBIAL RESISTANCE - BACTERIAL PERSISTENCE AND POSITIVE FUNCTION RESISTANCE [J].
BRYAN, LE .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1989, 23 (06) :817-820
[2]   PERSISTENCE OF PSEUDOMONAS-AERUGINOSA DURING CIPROFLOXACIN THERAPY OF A CYSTIC-FIBROSIS PATIENT - TRANSIENT RESISTANCE TO QUINOLONES AND PROTEIN-F-DEFICIENCY [J].
CHAMBERLAND, S ;
MALOUIN, F ;
RABIN, HR ;
SCHOLLAARDT, T ;
PARR, TR ;
BRYAN, LE .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1990, 25 (06) :995-1010
[3]   PERSISTENCE MECHANISMS IN PSEUDOMONAS-AERUGINOSA FROM CYSTIC-FIBROSIS PATIENTS UNDERGOING CIPROFLOXACIN THERAPY [J].
DIVER, JM ;
SCHOLLAARDT, T ;
RABIN, HR ;
THORSON, C ;
BRYAN, LE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (08) :1538-1546
[4]   HETEROGENEITY, PERSISTENCE, AND DISTRIBUTION OF PSEUDOMONAS-AERUGINOSA GENOTYPES IN CYSTIC-FIBROSIS PATIENTS [J].
FEGAN, M ;
FRANCIS, P ;
HAYWARD, AC ;
FUERST, JA .
JOURNAL OF CLINICAL MICROBIOLOGY, 1991, 29 (10) :2151-2157
[5]   RAPID EMERGENCE OF RESISTANCE IN PSEUDOMONAS-AERUGINOSA IN CYSTIC-FIBROSIS PATIENTS DUE TO INVIVO SELECTION OF STABLE PARTIALLY DEREPRESSED BETA-LACTAMASE PRODUCING STRAINS [J].
GIWERCMAN, B ;
LAMBERT, PA ;
ROSDAHL, VT ;
SHAND, GH ;
HOIBY, N .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1990, 26 (02) :247-259
[6]  
GROTHUES D, 1988, J CLIN MICROBIOL, V26, P115
[7]   DETECTION OF RESTRICTION-FRAGMENT-LENGTH-POLYMORPHISMS IN CLINICAL ISOLATES AND SERIALLY PASSAGED PSEUDOMONAS-AERUGINOSA STRAINS [J].
HJELM, LN ;
BRANSTROM, AA ;
WARREN, RL .
JOURNAL OF CLINICAL MICROBIOLOGY, 1990, 28 (10) :2178-2182
[8]  
KELLY NM, 1982, LANCET, V2, P688
[9]   AMINOGLYCOSIDE RESISTANCE IN PSEUDOMONAS-AERUGINOSA ISOLATED FROM CYSTIC-FIBROSIS PATIENTS [J].
MCNEILL, WF ;
JOHN, JF ;
TWITTY, JA .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1984, 81 (06) :742-747
[10]   DEVELOPMENT OF RESISTANCE IN PSEUDOMONAS-AERUGINOSA TO IMIPENEM, NORFLOXACIN, AND CIPROFLOXACIN DURING THERAPY - PROOF PROVIDED BY TYPING WITH A DNA PROBE [J].
OGLE, JW ;
RELLER, LB ;
VASIL, ML .
JOURNAL OF INFECTIOUS DISEASES, 1988, 157 (04) :743-748